TherapeuticsMD (TXMD)
NASDAQ:TXMD
Want to see TXMD full AI Analyst Report?
Top Page
TherapeuticsMD
(NASDAQ:TXMD)
Select Model
Select Model
Rating:51Neutral
Price Target:
$2.00
▲(19.05% Upside)
Action:Reiterated
Date:05/14/26
The score is driven primarily by improving financial stability (better cash flow and low leverage) but is held back by declining TTM revenue and continued operating losses. Technical signals are weak (negative MACD and price below key moving averages), and valuation is demanding (high P/E with no dividend yield provided). Corporate updates are constructive on profitability/cost control, but strategic-alternatives uncertainty limits the uplift.
Positive Factors
Balance Sheet Strength
Low leverage and positive equity materially reduce solvency risk and give management durable financial flexibility. A stronger balance sheet supports runway for commercialization, R&D or strategic transactions and cushions the business during revenue volatility over the next several months.
Negative Factors
Declining Revenue Trend
A persistent top-line decline reduces scale advantages and limits the ability to absorb fixed costs. Over several months this can erode gross profit base, constrain reinvestment, and make current cash-flow improvements harder to sustain without new growth drivers.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Low leverage and positive equity materially reduce solvency risk and give management durable financial flexibility. A stronger balance sheet supports runway for commercialization, R&D or strategic transactions and cushions the business during revenue volatility over the next several months.
Read all positive factors
TherapeuticsMD (TXMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$23.15M
Dividend YieldN/A
Average Volume (3M)310.58K
Price to Earnings (P/E)61.5
Beta (1Y)1.12
Revenue Growth82.13%
EPS GrowthN/A
CountryUS
Employees1
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.02
Shares Outstanding11,574,362
10 Day Avg. Volume897,126
30 Day Avg. Volume310,579
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)0.70
Price to Sales (P/S)6.24
P/FCF Ratio7.78
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue5.90
Enterprise Value/Gross Profit6.53
Enterprise Value/Ebitda-5.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)$9.30M
TherapeuticsMD Business Overview & Revenue Model
Company Description
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progestero...
How the Company Makes Money
null...
TherapeuticsMD Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
68
Positive
Cash Flow
56
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.35M | 3.02M | 1.76M | 1.30M | 69.96M | 2.57M |
| Gross Profit | 3.03M | 3.02M | 1.76M | 1.30M | 68.57M | 1.17M |
| EBITDA | -3.71M | -3.02M | -2.98M | -8.08M | 11.86M | -70.84M |
| Net Income | 179.00K | -569.00K | -2.18M | -10.28M | 112.00M | -172.41M |
Balance Sheet | ||||||
| Total Assets | 37.58M | 37.66M | 38.82M | 43.31M | 90.46M | 169.47M |
| Cash, Cash Equivalents and Short-Term Investments | 8.42M | 7.48M | 5.06M | 4.33M | 38.07M | 64.91M |
| Total Debt | 4.82M | 5.12M | 7.17M | 8.01M | 8.76M | 197.69M |
| Total Liabilities | 10.61M | 10.78M | 11.45M | 14.02M | 55.31M | 263.09M |
| Stockholders Equity | 26.97M | 26.88M | 27.37M | 29.29M | 35.14M | -93.62M |
Cash Flow | ||||||
| Free Cash Flow | 2.67M | 2.42M | 732.00K | 0.00 | -4.43M | -147.84M |
| Operating Cash Flow | 2.67M | 2.42M | 732.00K | -48.14M | -4.08M | -147.81M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 223.48M | -2.22M |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 3.15M | -235.21M | 134.67M |
TherapeuticsMD Technical Analysis
Positive
1.68
Price Trends
2.11
Negative
2.15
Negative
1.72
Positive
Market Momentum
-0.04
Positive
46.50
Neutral
46.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TXMD, the sentiment is Positive. The current price of 1.68 is below the 20-day moving average (MA) of 2.06, below the 50-day MA of 2.11, and below the 200-day MA of 1.72, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 46.50 is Neutral, neither overbought nor oversold. The STOCH value of 46.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TXMD.
TherapeuticsMD Risk Analysis
TherapeuticsMD disclosed 49 risk factors in its most recent earnings report. TherapeuticsMD reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
TherapeuticsMD Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $23.15M | 61.52 | 0.27% | ― | 82.13% | ― | |
47 Neutral | $23.51M | -1.28 | -107.16% | ― | -18.24% | -2264.65% | |
44 Neutral | $5.35M | ― | ― | ― | ― | ― | |
42 Neutral | $1.04M | -0.70 | -404.42% | ― | ― | ― |
* Healthcare Sector Average
TXMD
TherapeuticsMD
2.02
0.53
35.57%
PRPH
Prophase Labs
0.11
-3.17
-96.64%
RDHL
RedHill Biopharma
0.93
-0.97
-50.89%
AYTU
Aytu BioScience
2.10
0.07
3.45%
GELS
Gelteq Limited
0.41
-1.31
-76.32%
TherapeuticsMD Corporate Events
Business Operations and StrategyFinancial Disclosures
TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives
Positive
May 12, 2026
TherapeuticsMD, Inc. reported on May 12, 2026, that it generated $103,000 in net income from continuing operations for the quarter ended March 31, 2026, reversing a net loss of $636,000 a year earlier. License revenue rose to $724,000, driven main...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy
Positive
Mar 31, 2026
On March 30, 2026, TherapeuticsMD reported full-year 2025 results, showing net loss from continuing operations narrowed to $0.7 million, or $0.06 per share, from $2.3 million, or $0.20 per share, in 2024. License revenue, mainly from its Mayne agr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.